Item 8.01. Other Events

On November 15, 2021, Humacyte, Inc. (the "Company") issued a press release announcing data from a Phase 2 clinical trial of patients receiving the human acellular vessel (HAV) produced using the Company's cutting-edge, large-scale manufacturingsystems, known as "LUNA200," for vascular access in hemodialysis. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits





(d) Exhibits.



Exhibit
Number     Description
  99.1       Press release, dated November 15, 2021.

104        Cover Page Interactive Data File (embedded within the Inline XBRL document).




                                       1

© Edgar Online, source Glimpses